9-[beta-D-Ribopyranosyl]-adenine | 10563-76-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 9-[beta-D-Ribopyranosyl]-adenine
• 英文别名: 9-(β-D-ribopyranosyl)adenine；9-β-D-ribopyranosyladenine；1-(6-amino-purin-9-yl)-β-D-1-deoxy-ribopyranose；D-(1R)-1-(6-amino-purin-9-yl)-1,5-anhydro-ribitol；D-(1R)-1-(6-Amino-purin-9-yl)-1,5-anhydro-ribit；(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)oxane-3,4,5-triol
• CAS: 10563-76-5
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.244
• InChiKey: PIYAXTGSPRHBFB-KQYNXXCUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9-[beta-D-Ribopyranosyl]-adenine 在 溶剂黄146 、 sodium nitrite 作用下， 生成 9-(3,4,5-trihydroxyoxan-2-yl)-3H-purin-6-one
  参考文献：
  名称：

  Baddiley et al., Journal of the Chemical Society, 1944, p. 657

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 吡啶 作用下， 生成 9-[beta-D-Ribopyranosyl]-adenine
  参考文献：
  名称：

  183.嘌呤核苷合成的实验。第十三部分。一种改进的4-糖苷氨基-5-硫代甲酰胺基嘧啶环化方法

  摘要：

  DOI：

  10.1039/jr9460000852

文献信息

• Direct One-Pot Synthesis of Nucleosides from Unprotected or 5-<i>O</i>-Monoprotected <scp>d</scp>-Ribose
  作者：A. Michael Downey、Celin Richter、Radek Pohl、Rainer Mahrwald、Michal Hocek

  DOI：10.1021/acs.orglett.5b02332

  日期：2015.9.18

  implications in life and disease. Current synthetic methods involve multistep procedures employing protected sugars in the glycosylation of nucleobases. Using modified Mitsunobu conditions, we report on the first direct glycosylation of purine and pyrimidine nucleobases with unprotected d-ribose to provide β-pyranosyl nucleosides and a one-pot strategy to yield β-furanosides from the heterocycle and 5-O-monoprotected

  新的，改进的获取核苷的方法不仅对有机化学家而且对整个科学界都普遍感兴趣，因为它们对生命和疾病具有关键意义。当前的合成方法涉及在核碱基的糖基化中采用受保护的糖的多步骤程序。使用改性的Mitsunobu条件下，我们对嘌呤的第一个直接的糖基化报告，并嘧啶核碱基与未受保护的d -核糖提供β-吡喃核苷和一锅策略以产生β-呋喃糖苷从杂环和5- ö -monoprotected d -核糖。
• Pentopyranosylnucleoside, its preparation and use
  申请人：Nanogen Recognomics GmbH

  公开号：US20040198966A1

  公开（公告）日：2004-10-07

  The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II) 1 their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.

  本发明涉及一种式（I）或式（II）的五糖基嘌呤核苷，以及它们的制备和用于制备治疗、诊断和/或电子组件的用途。
• Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
  申请人：Ealick E. Steven

  公开号：US20050214901A1

  公开（公告）日：2005-09-29

  A host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside cleavage enzymes is provided. The transformed or transfected host cell can be used in combination with a purine substrate to treat tumour cells and/or virally infected cells. A nucleotide sequence encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth is also provided. A method is detailed for the delivery of toxin by generation withing target cells or by administration and delivery to the cells from without. Novel purine nucleosides are detailed that yield a cytotoxic purine upn enzymatic cleavage. A synthetic process for nucleosides is also detailed.

  提供了一种由载有突变嘌呤核苷酸裂解酶编码DNA序列的载体转化或转染的宿主细胞。该转化或转染的宿主细胞可与嘌呤底物结合，用于治疗肿瘤细胞和/或病毒感染的细胞。还提供了编码突变E. coli来源的嘌呤核苷酰化酶蛋白的核苷酸序列，可与适当的底物结合使用，产生有害细胞生长的毒素。详细介绍了一种通过靶细胞内生成或通过外部给药和传递给细胞的毒素递送方法。详细介绍了产生细胞毒性嘌呤核苷酶裂解产物的新型嘌呤核苷。还详细介绍了一种核苷的合成过程。
• Pentopyranosyl nucleic acid arrays, and uses thereof
  申请人：Aventis Research and Technologies GmbH & Co. KG

  公开号：US20030039997A1

  公开（公告）日：2003-02-27

  The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II) 1 their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.

  本发明涉及公式（I）或公式（II）的五糖基嘌呤核苷，以及它们的制备和用于生产治疗、诊断和/或电子组件。
• Process for the preparation of a pentopyranosyl conjugate
  申请人：Miculka Christian

  公开号：US20050053945A1

  公开（公告）日：2005-03-10

  The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II) their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.

  本发明涉及公式(I)或公式(II)的五碳杂环核苷的制备及其用于制备治疗、诊断和/或电子组件。